Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 9/20 | 0.36 |
| ▸ | CA1 | P00915 | 8/20 | 0.36 |
| ▸ | CA2 | P00918 | 8/20 | 0.36 |
| ▸ | CA12 | O43570 | 6/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4631204 | 0.96 | PTGER3 (0.35) | CA9CA1CA2CA12PTGER3 | |
| SCHEMBL4630116 | 0.90 | CA9 (0.38) | CA9CA1CA2CA12PTGER3 | |
| SCHEMBL4630833 | 0.86 | ALDH1A1 (0.38) | CA9CA1CA2CA12PTGER3 | |
| SCHEMBL4631207 | 0.85 | PTGER3 (0.37) | CA9CA1CA2CA12PTGER3 | |
| SCHEMBL4937655 | 0.82 | ALDH1A1 (0.37) | CA9CA1CA2CA12PTGER3 | |
| SCHEMBL4631634 | 0.80 | ALDH1A1 (0.38) | CA9CA1CA2CA12PTGER3 | |
| SCHEMBL25941924 | 0.74 | CA9 (0.52) | CA9CA1CA2CA12PTGER3 | |
| SCHEMBL4630027 | 0.69 | CA9 (0.46) | CA9CA1CA2CA12ESR1 | |
| SCHEMBL4631632 | 0.69 | ALDH1A1 (0.37) | CA9CA1CA2CA12PTGER3 | |
| SCHEMBL14008335 | 0.67 | KDM4E (0.51) | MAPTKMT2AABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275215-A1 | Fluorescein-Based Compounds And Their Use For Peptide Synthesis | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2008-11-06 | — | — | US | disclosed |
| EP-1749870-B1 | Fluorescein-based compounds and their use for peptide synthesis | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2008-05-14 | — | — | EP | disclosed |
| EP-1749870-A1 | Fluorescein-based compounds and their use for peptide synthesis | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275215-A1 | Fluorescein-Based Compounds And Their Use For Peptide Synthesis | DNPEP, ANPEP, PEPD | CA9 1617/4885CA1 1158/4885CA2 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.